HDAC inhibitors have been developed very rapidly in clinical trials and even in approvals for treating several cancers. However, there are few reported HDAC inhibitors designed from Nε-acetyl lysine. In current study, we raised a novel design, which is about Nε-acetyl lysine analogues containing amide acetyl groups with the hybridization of ZBG groups as novel HDAC inhibitors.